1.Progress of research on the role of primary cilia in cartilage degeneration in temporomandibular joint osteoarthritis
Gongchen LI ; Ziyue HU ; Yao SUN
STOMATOLOGY 2024;44(6):448-451
Temporomandibular joint osteoarthritis(TMJOA)is characterized by progressive cartilage degeneration,subchondral bone remodeling,chronic inflammation in the synovial tissue and osteophyte formation.Chondrocyte apoptosis is one of the main factors of cartilage degeneration.Prevention and treatment of TMJOA can be achieved by inhibiting premature or excessive chondrocyte apoptosis.Primary cilia protruding from the surface of chondrocytes can sense mechanical stimulation and induce chondrocyte differentiation.Stud-ying the role of primary cilia in TMJOA will help us understand the pathogenesis of TMJOA and construct a reasonable and effective treatment strategy.
2.A case of hepatic angiosarcoma with Kasabach-Merritt syndrome
Mengnan LI ; Gongchen WANG ; Zhiming ZHANG
Journal of Clinical Hepatology 2021;37(11):2646-2648
3. Effects of remimazolam on early postoperative cognitive function in elderly patients with hip fracture
Gongchen DUAN ; Jimin WU ; Qiaomin XU ; Jianxin JIANG ; Haiyan LAN ; Xutong ZHANG ; Kaiming YUAN ; Jun LI
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(2):146-153
AIM: To evaluate the effect of remimazolam on early postoperative cognitive function in elderly patients with hip fracture based on a randomized controlled trial. METHODS: A total of 106 elderly patients, aged 65-90 years, ASA grade Ⅱ or III, who underwent hip fracture surgery under combined spinal-epidural anesthesia in the Sixth Affiliated Hospital of Wenzhou Medical University from December 2022 to June 2023 and met the inclusion criteria, were selected and randomized into remimazolam group (group R) and propofol group (group P) according to the random number table, with 53 cases in each group. Patients in group P received a slow intravenous injection of propofol at a dose of 0.3-0.5 mg / kg (injection time of 1min), followed by a pump infusion at 0.5-3 mg · kg
4.LncRNA Nron regulates osteoclastogenesis during orthodontic bone resorption.
Ruilin ZHANG ; Junhui LI ; Gongchen LI ; Fujun JIN ; Zuolin WANG ; Rui YUE ; Yibin WANG ; Xiaogang WANG ; Yao SUN
International Journal of Oral Science 2020;12(1):14-14
Activation of osteoclasts during orthodontic tooth treatment is a prerequisite for alveolar bone resorption and tooth movement. However, the key regulatory molecules involved in osteoclastogenesis during this process remain unclear. Long noncoding RNAs (lncRNAs) are a newly identified class of functional RNAs that regulate cellular processes, such as gene expression and translation regulation. Recently, lncRNAs have been reported to be involved in osteogenesis and bone formation. However, as the most abundant noncoding RNAs in vivo, the potential regulatory role of lncRNAs in osteoclast formation and bone resorption urgently needs to be clarified. We recently found that the lncRNA Nron (long noncoding RNA repressor of the nuclear factor of activated T cells) is highly expressed in osteoclast precursors. Nron is downregulated during osteoclastogenesis and bone ageing. To further determine whether Nron regulates osteoclast activity during orthodontic treatment, osteoclastic Nron transgenic (Nron cTG) and osteoclastic knockout (Nron CKO) mouse models were generated. When Nron was overexpressed, the orthodontic tooth movement rate was reduced. In addition, the number of osteoclasts decreased, and the activity of osteoclasts was inhibited. Mechanistically, Nron controlled the maturation of osteoclasts by regulating NFATc1 nuclear translocation. In contrast, by deleting Nron specifically in osteoclasts, tooth movement speed increased in Nron CKO mice. These results indicate that lncRNAs could be potential targets to regulate osteoclastogenesis and orthodontic tooth movement speed in the clinic in the future.
Animals
;
Bone Resorption
;
genetics
;
Mice
;
Mice, Inbred C57BL
;
Osteoclasts
;
Osteogenesis
;
RANK Ligand
;
RNA, Long Noncoding
;
genetics
5. A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection
Yinghui GAO ; Guangming LI ; Qinglong JIN ; Yingren ZHAO ; Zhansheng JIA ; Xiaorong MAO ; Yongfeng YANG ; Jia SHANG ; Gongchen WANG ; Wen XIE ; Shanming WU ; Mingxiang ZHANG ; Jinlin HOU ; Dongliang LI ; Yuemin NAN ; Yujuan GUAN ; Chunxia ZHU ; Yangzhou YUAN ; Lai WEI
Chinese Journal of Hepatology 2019;27(5):352-357
Objective:
To evaluate the efficacy and safety of sofosbuvir (Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.) combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection.
Methods:
Treatment-naïve or treatment experienced genotype 2 chronic hepatitis C patients from sixteen research centers of China were screened. All subjects received once-daily dose of sofosbuvir (400 mg) combined with ribavirin (body weight < 75 kg, 1 000 mg/day, 400 mg in the morning and 600 mg in the evening; body weight > 75 kg, 1 200 mg/d, 600 mg in the morning and 600 mg in the evening) for 12 weeks. Patients were followed-up for a period of 12 weeks after discontinuation of treatment. Continuous variables were expressed as mean ± standard deviation. The proportion of subjects with virologic response at different follow-up time points and 95% confidence intervals were estimated by maximum likelihood ratio and Clopper-Pearson interval.
Results:
132 cases with genotype 2 chronic hepatitis C virus infection from sixteen research centers of China were included, 12 cases of whom were associated with cirrhosis, and the remaining 120 cases were not associated with cirrhosis. One hundred and thirty-one cases completed the study, and one patient lost to follow-up at week 4 after the end of treatment. The sustained virological response rate was 96.2% (95% confidence interval: 92.37% - 99.16%) after 12 weeks of drug withdrawal. Virological relapse occurred in four cases. Of the 132 subjects enrolled in the study, 119 (90.2%) reported 617 adverse events during treatment, of which 359 (76.5%) were TEAE related to sofosbuvir and/or ribavirin. There were nine TEAEs of grade 3 and above, and six cases (4.5%) of them had six severe adverse events. Only one serious adverse event was associated with sofosbuvir and ribavirin (unstable angina pectoris). There were no adverse events leading to drug discontinuation or death.
Conclusion
Sofosbuvir combined with ribavirin has a high SVR rate in the treatment of genotype 2 chronic hepatitis C virus infection, and most of the adverse events occurred were mild with acceptable safety profile.
6.Primary cilia support cartilage regeneration after injury.
Dike TAO ; Lei ZHANG ; Yunpeng DING ; Na TANG ; Xiaoqiao XU ; Gongchen LI ; Pingping NIU ; Rui YUE ; Xiaogang WANG ; Yidong SHEN ; Yao SUN
International Journal of Oral Science 2023;15(1):22-22
In growing children, growth plate cartilage has limited self-repair ability upon fracture injury always leading to limb growth arrest. Interestingly, one type of fracture injuries within the growth plate achieve amazing self-healing, however, the mechanism is unclear. Using this type of fracture mouse model, we discovered the activation of Hedgehog (Hh) signaling in the injured growth plate, which could activate chondrocytes in growth plate and promote cartilage repair. Primary cilia are the central transduction mediator of Hh signaling. Notably, ciliary Hh-Smo-Gli signaling pathways were enriched in the growth plate during development. Moreover, chondrocytes in resting and proliferating zone were dynamically ciliated during growth plate repair. Furthermore, conditional deletion of the ciliary core gene Ift140 in cartilage disrupted cilia-mediated Hh signaling in growth plate. More importantly, activating ciliary Hh signaling by Smoothened agonist (SAG) significantly accelerated growth plate repair after injury. In sum, primary cilia mediate Hh signaling induced the activation of stem/progenitor chondrocytes and growth plate repair after fracture injury.
Mice
;
Animals
;
Hedgehog Proteins/genetics*
;
Receptors, G-Protein-Coupled/metabolism*
;
Cilia/metabolism*
;
Cartilage/metabolism*
;
Regeneration